Nuvalent, Inc. (NUVL)
NASDAQ: NUVL · IEX Real-Time Price · USD
78.96
-0.87 (-1.09%)
At close: Jul 19, 2024, 4:30 PM
79.03
+0.07 (0.09%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Nuvalent Employees
Nuvalent had 92 employees as of December 31, 2023. The number of employees increased by 30 or 48.39% compared to the previous year.
Employees
92
Change (1Y)
30
Growth (1Y)
48.39%
Revenue / Employee
n/a
Profits / Employee
-$1,581,620
Market Cap
5.10B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 92 | 30 | 48.39% |
Dec 31, 2022 | 62 | 22 | 55.00% |
Dec 31, 2021 | 40 | 13 | 48.15% |
Dec 31, 2020 | 27 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Select Medical Holdings | 54,600 |
PACS Group | 32,433 |
R1 RCM | 30,000 |
DENTSPLY SIRONA | 15,000 |
Organon & Co. | 10,000 |
Option Care Health | 7,802 |
Merit Medical Systems | 6,950 |
Doximity | 827 |
NUVL News
- 1 hour ago - Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor - PRNewsWire
- 6 days ago - Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024 - PRNewsWire
- 11 days ago - Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer - PRNewsWire
- 7 weeks ago - Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference - PRNewsWire
- 2 months ago - Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655 - PRNewsWire
- 2 months ago - Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results - PRNewsWire
- 3 months ago - Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 - PRNewsWire
- 4 months ago - Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024 - PRNewsWire